Opes Acquisition Corp. Files Definitive Proxy to Extend
by Kristi Marvin on 2019-09-04 at 6:22pm

Opes Acquisition Corp. (OPES), a Mexico-focused SPAC, filed their definitive proxy tonight ahead of their shareholder vote to extend their completion deadline, scheduled for Monday, September 16th. Previously, OPES had filed their preliminary proxy back on August 23rd, but there were a number of blanks throughout that document.  Now that we have additional information, we have a (slightly) clearer picture.

First up, Opes is only asking for a two-month extension to November 15th.  Not three months, not six months, but only two short months. When you ask for a short extension WITHOUT an announced deal, well, that generally means they’re probably going to announce something ASAP.  However, even if they announce something tomorrow, closing a transaction in two months time is very aggressive.  So it’s still a bit curious.  Why not just ask for three months and give the SPAC some breathing room to close?  Or, could it be that they don’t have a deal yet and they decided that if they can’t lock something up within the next two months, they’d rather throw in the towel?  The former is more likely, but still….that two months is odd.  It’s like trying to finish a jigsaw puzzle and you can’t find the last missing piece.

However, Opes isn’t taking any chances with their cash in trust by providing a straight contribution to trust for shareholders who do not redeem with the contribution being $0.0333 per share per month.  The current estimated redemption value is $10.34 with a trust value of approximately $119 million, but if OPES needs the full two months (which they should), that extra $0.0666 brings it to $10.41 + interest, or approximately $10.43.

In summary, this should be a fairly straightforward extension vote with a minimal amount of redemptions.  However, if OPES doesn’t announce a deal by at least the week after their vote (September 16th), they’re either going to have to extend again or liquidate.  Let’s hope we get some good news.

For reference, the Record Date is August 28th, with a redemption deadline of September 12th.

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved